SIR, AdvaMed, Philips, Abbott and others in the Office-Based Facility Association contend more must be done to reverse these trends and protect private practices.

The Missouri complaint mirrors those brought by the Federal Trade Commission, the state of Texas and Philadelphia-based Jefferson Health, among others, in that it’s focused on alleged collusion between pharmacy benefit managers and drug companies to control the price of insulin. 

Boston Scientific sent all known customers a letter on December 19, 2025 alerting them to an issue with certain AXIOS Stent and Electrocautery Enhanced Delivery Systems. During deployment, the stents may not expand. This can cause severe, potentially life-threatening injury to patients. All recalled stents must be removed from clinical settings immediately. 

The FDA finalized four Class I recalls related to safety concerns first reported by Abbott in November. Meanwhile, a Florida man who uses these sensors to manage his diabetes has already filed a lawsuit over the issue.

MedPAC, an independent panel of experts that advises lawmakers on payment policy, is endorsing an additional 0.5% update to doc pay, the AMA reports.  

President Trump’s outline is largely an exercise in thinking out loud since it can’t propel anything consequential without legislative action in Congress. Still, the plan—and the reactions it’s eliciting—warrant a look. 

The insurer is planning to reduce reimbursement timelines for hospitals in Oklahoma, Idaho, Minnesota and Missouri from 30 days to 15. The details are unclear, but the company said the framework could extend nationwide.

The California-based health system faced multiple accusations of upcoding diagnoses to receive additional risk-adjusted payments from the Medicare Advantage program. Its payer plan and providers were implicated in what the DOJ described as systemic fraud. Kaiser Permanente denies any wrongdoing.